Alera Bio

06/05/2026

Alera Bio announces the appointment of David McCullough as Chief Executive Officer.

David is an accomplished biotechnology executive with extensive experience in corporate strategy, capital formation, operational ex*****on, and the advancement of emerging therapeutics companies. He has successfully guided biotechnology organizations through critical stages of growth, financing, and strategic development.

As CEO, David will lead Alera Bio’s corporate strategy, financing initiatives, organizational development, and ex*****on of the company’s clinical and regulatory roadmap as we advance AB-101 for MCT-8 deficiency (Allan-Herndon-Dudley Syndrome).

“Alera Bio represents an extraordinary opportunity to bring hope to families affected by one of the most devastating rare neurodevelopmental disorders,” said David McCullough.

We are excited to welcome David to the Alera Bio team and look forward to the next chapter of growth and progress.

Read the press release here: https://lnkd.in/gr6VcqKi

04/09/2026

We are excited to announce that Alera Bio has entered into an exclusive licensing agreement with BLA Technology, LLC.

This agreement expands our intellectual property platform supporting the development of therapies for MCT-8 deficiency (Allan-Herndon-Dudley Syndrome).

By securing rights to key technologies in thyroid hormone biology, we are strengthening our ability to develop therapies that address both the neurological and systemic aspects of this devastating disease.

This milestone reinforces our commitment to rare disease and our mission to bring meaningful solutions to patients and families.

Read the full announcement at https://www.pr.com/press-release/965253

04/08/2026

Alera Bio is pleased to announce the appointment of Andrew Eisen, MD, PhD as Chief Scientific Officer.

Dr. Eisen is a seasoned physician-scientist with over 20 years of experience spanning preclinical research through early-stage clinical development. His expertise in neuroscience, metabolic disease, and translational medicine aligns directly with our mission to develop transformative therapies for patients with rare neurological disorders.

In his new role, Dr. Eisen will lead the advancement of AB-101, our novel multi-mechanism therapy for MCT-8 deficiency — a devastating ultra-rare condition with no approved treatments addressing neurological symptoms.

We are excited to have him join the team at this important stage as we work toward bringing new hope to patients and families.

Read more at https://www.pr.com/press-release/965111

02/28/2026

It's Rare Disease Day 2026! Join Rare Disease Day and us as we raise awareness about the 300 million people living with any one of the over 6,000 identified rare diseases.

02/06/2026

With the passage of the Give Kids a Chance Act, the Rare Pediatric Disease Priority Review Voucher (PRV) program has now been reauthorized, reinforcing a critical incentive for companies advancing therapies for children with serious, rare conditions. It is a win for the MCT-8 families who have waited far too long for progress.

In 2024, Alera’s lead program, AB-101 for MCT-8 deficiency, received Rare Pediatric Disease Designation (RPDD) from the FDA. This designation, now paired with a reauthorized PRV pathway, represents more than a regulatory milestone. It validates the urgency of this disease, strengthens the development pathway, and reinforces our commitment to advancing a therapy for children who currently have no approved treatment options.

We are grateful to the advocates, clinicians, policymakers, and researchers who made this reauthorization possible, and we remain focused on translating this momentum into meaningful outcomes for patients.

11/14/2025

Introducing the New AleraBio.com

We’re excited to share our redesigned website: www.alerabio.com

What’s new:
Our lead program AB-101 for MCT-8 deficiency
Patient resources for families navigating rare diseases
A fresh design that reflects our mission and vision

Explore the new site and learn how we’re advancing therapies for patients with urgent unmet needs.

Biology drives us. Patients define us.

Visit now: www.alerabio.com

11/11/2025

Alera Bio announces its inaugural Board of Directors
We are proud to introduce the accomplished leaders joining our Board:
• Stephen Hill, BSc, MB, ChB – Director
• Mark Prygocki – Director
• Renny Griffith, MD – Director & Investor
• Cassius Coleman – Director & Investor

Together, they bring deep expertise in biotech leadership, commercialization, clinical practice, finance, and governance. Their guidance will be invaluable as Alera Bio advances AB-101 in MCT-8 deficiency and builds a sustainable rare disease company.

Read the press release here: https://www.pr.com/press-release/953303

09/26/2025

An executive team built on experience and focused on impact

Today, we announce the formation of our executive leadership team - leaders who have collectively launched dozens of therapies, raised significant capital, and guided companies from discovery through commercialization.

With deep expertise in biotech innovation, regulatory strategy, and rare disease development, this team brings both the vision and ex*****on required to deliver on our mission.

Together, they position Alera Bio to accelerate progress for patients and set the foundation for sustained growth.

Meet the team: https://www.pr.com/press-release/949513

09/20/2025

Alera Bio has entered an exclusive licensing agreement with BLA Technology, LLC to advance AB-101, our lead program for MCT-8 deficiency (Allan-Herndon-Dudley Syndrome).

MCT-8 deficiency is a devastating, ultra-rare neurological disorder that affects ~1 in 70,000 males worldwide. It leads to profound neurodevelopmental delays, severe motor dysfunction, cognitive
impairment, and systemic thyroid complications. Today, there are no approved therapies.

AB-101 has already received FDA Rare Pediatric Disease designation and is being advanced as a program designed to address both neurological and endocrinological symptoms — a dual-impact approach that could transform care for patients and families.

As our Founder Frank Jaeger shared: “With MCT-8 deficiency as our lead program, we are advancing a pipeline that addresses urgent,
life-altering conditions.”

Read more about this milestone here: https://www.pr.com/press-release/948515

Biology drives us. Patients define us. ✨

Alera Bio secures exclusive license to advance AB-101, a first-in-class program for MCT-8 deficiency, with FDA Rare Pediatric Disease designation already in...

07/03/2025

We’ve launched!

Introducing Alera Bio — a new kind of biotech company, built to deliver transformative treatments for the most overlooked neurological diseases.
• Science-led
• Patient-powered
• Urgency-driven
• Focused on rare, pediatric, and genetic brain disorders

Because when time is the enemy, science needs to move faster.
Chicago-based | Globally focused
Learn more: www.alerabio.com